Download logo
“In the last three years, we have witnessed significant progress, but women in poorer countries and poor and marginalized women in richer countries still suffer disproportionately from cervical cancer,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “With enhanced strategies to increase access to vaccination, screening and treatment, strong political and financial commitment from countries, and increased support from partners, we can realize our vision for eliminating cervical cancer.”
Governments and communities are leading the way by declaring commitment and developing strategies to eliminate cervical cancer and countries around the world are rallying behind WHO’s call to action on 17 November.
Strong progress on HPV vaccination
Since the launch of the Global strategy to accelerate the elimination of cervical cancer as a public health problem three years ago, a further 30 countries, including countries with large populations and cervical cancer burden such as Bangladesh, Indonesia and Nigeria, introduced the HPV vaccine. As of today, 140 countries have introduced HPV vaccine into national immunization programmes.
The global HPV vaccination coverage of girls that received at least one dose of HPV vaccine has increased to 21% in 2022 – exceeding the pre-pandemic levels for the first time. If this rate of progress is maintained the world would be on track to meet the 2030 target to make HPV vaccines available to all girls everywhere.
WHO, in collaboration with GAVI and other partners, has initiated systematic efforts to catch-up vaccinations for girls who missed HPV vaccination as a result of pandemic disruptions and to revitalize HPV vaccination programmes towards reaching the 90% coverage target.
In Nigeria, for example, HPV vaccine was introduced into the routine immunization programme with a single-dose schedule in October 2023. The country aims to vaccinate 7.7 million girls – the largest number in a single round of HPV vaccination in the region.
Weak progress on screening and treatment
Countries have invested to improve access to screening all over the world. This year, together with Unitaid and its implementing partners, Ministries of Health in 14 low- and middle-income countries reached a milestone of screening over a million women.
In most countries, those diagnosed with cervical cancer still need better access to surgery, radiotherapy, chemotherapy and palliative care. Still, only 65% of countries include cervical cancer screening services and 69% include radiotherapy for treatment of cervical cancer in the health benefit packages as part of universal health coverage schemes.
However, pioneering country experiences showcase progress that is being made on the ground:
To enhance screening quality, reduce costs and broaden access to health-care services, WHO now endorses HPV testing as the preferred method for cervical cancer screening. This includes support for self-sampling, which makes screening even more convenient. In addition, WHO prequalified a fourth HPV test in June 2023, providing an additional option for countries seeking to implement advanced screening methods to identify patients requiring treatment more effectively.
Distributed by APO Group on behalf of World Health Organization (WHO).
This website uses cookies.